肝脏血管生成素-2是丙型肝炎病毒直接抗病毒药物治疗后新发或复发性肝细胞癌的关键预测因子
研究纳入242例接受直接抗病毒药物(DAA)治疗的晚期纤维化慢性丙型肝炎患者,发现肝硬化患者中既往肝癌者复发率50.0%(14/28),新发肝癌率13.5%(21/155)。肝组织血管生成素-2(ANGPT2)表达独立预测肝癌复发(OR 1.137)或新发(OR 1.604)。第二项257例不同病因肝硬化前瞻性研究中,DAA治疗(OR 4.770)和大型静脉曲张(OR 3.857)是新发肝癌的独立预测因子。
要点
- 肝硬化丙型肝炎患者DAA治疗后,既往肝癌者复发率50.0%,新发肝癌率13.5%。
- 肝组织ANGPT2表达独立预测肝癌复发(OR 1.137)和新发(OR 1.604)。
- 不同病因肝硬化中,DAA治疗(OR 4.770)和大型静脉曲张(OR 3.857)预测新发肝癌。
核心结论
- DAA介导的VEGF升高可能促进易感患者(纤维化更重、侧支循环形成、肝组织新生血管通路已异常激活如ANGPT2升高)的肝癌复发或发生。
研究设计与样本
- 研究1:242例接受DAA治疗的晚期纤维化慢性丙型肝炎患者,研究肝脏促血管生成微环境。
- 研究2:257例不同病因肝硬化患者的前瞻性研究,寻找新发肝癌相关因素。
- 两项研究均进行生化、临床、血流动力学、内镜、弹性成像和回声多普勒检查。
主要发现
- 研究1中无肝硬化患者均未发生肝癌;183例肝硬化患者中,既往肝癌者28例中14例(50.0%)复发,无既往肝癌者155例中21例(13.5%)新发肝癌。
- 复发和新发肝癌患者肝纤维化评分、门静脉压力和全身炎症显著高于未复发或无肝癌患者。
- 复发/新发肝癌患者肿瘤和非肿瘤ANGPT2与门静脉流速呈负相关(r=-0.412,P=0.037;r=-0.409,P=0.047),与肝硬度呈正相关(r=0.526,P=0.007;r=0.525,P=0.003)。
- 基线循环VEGF与肝硬化肝组织ANGPT2显著相关(r=0.414,P=0.044);VEGF在DAA治疗期间升高,随访3个月时仍稳定升高,与血清ANGPT2显著相关(r=0.531,P=0.005)。
- DAA前原发肿瘤或肝硬化组织中ANGPT2表达独立与肝癌复发风险(OR 1.137,95%CI 1.044-1.137,P=0.003)或发生风险(OR 1.604,95%CI 1.080-2.382,P=0.019)相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Recent reports suggested that direct acting antivirals (DAAs) might favor hepatocellular carcinoma (HCC). In study 1, we studied the proangiogenic liver microenvironment in 242 DAA-treated chronic hepatitis C patients with advanced fibrosis. Angiopoietin-2 (ANGPT2) expression was studied in tissue (cirrhotic and/or neoplastic) from recurrent, de novo, nonrecurrent HCC, or patients never developing HCC. Circulating ANGPT2,vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) were also measured. In study 2, we searched for factors associated with de novo HCC in 257 patients with cirrhosis of different etiologies enrolled in a dedicated prospective study. Thorough biochemical, clinical, hemodynamic, endoscopic, elastographic, and echo-Doppler work-up was performed in both studies. In study 1, no patients without cirrhosis developed HCC. Of 183 patients with cirrhosis, 14 of 28 (50.0%) with previous HCC recurred whereas 21 of 155 (13.5%) developed de novo HCC. Patients with recurrent and de novo HCCs had significantly higher liver fibrosis (LF) scores, portal pressure, and systemic inflammation than nonrecurrent HCC or patients never developing HCC. In recurrent/de novo HCC patients, tumor and nontumor ANGPT2 showed an inverse relationship with portal vein velocity (PVv; r = -0.412, P = 0.037 and r = -0.409, P = 0.047 respectively) and a positive relationship with liver stiffness (r = 0.526, P = 0.007; r = 0.525, P = 0.003 respectively). Baseline circulating VEGF and cirrhotic liver ANGPT2 were significantly related (r = 0.414, P = 0.044). VEGF increased during DAAs, remaining stably elevated at 3-month follow-up, when it significantly related with serum ANGPT2 (r = 0.531, P = 0.005). ANGPT2 expression in the primary tumor or in cirrhotic tissue before DAAs was independently related with risk of HCC recurrence (odds ratio [OR], 1.137; 95% confidence interval [CI], 1.044-1.137; P = 0.003) or occurrence (OR, 1.604; 95% CI, 1.080-2.382; P = 0.019). In study 2, DAA treatment (OR, 4.770; 95% CI, 1.395-16.316; P = 0.013) and large varices (OR, 3.857; 95% CI, 1.127-13.203; P = 0.032) were independent predictors of de novo HCC. CONCLUSION: Our study indicates that DAA-mediated increase of VEGF favors HCC recurrence/occurrence in susceptible patients, that is, those with more severe fibrosis and splanchnic collateralization, who already have abnormal activation in liver tissues of neo-angiogenetic pathways, as shown by increased ANGPT2. (Hepatology 2018; 00:000-000).
引用
- Faillaci F, Marzi L, Critelli R, et al. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Hepatology. 2018. PMID: 29604220. doi:10.1002/hep.29911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。